

# following COVID-19 vaccination **Department of Psychiatry, Cleveland Clinic**

# **Case report of new onset mania with psychotic features** Amanda Pomerantz, DO, Adele C. Viguera, MD, Diana Lorenzo, MD, Anna P. Shapiro-Krew, MD

#### Introduction

• Neuropsychiatric manifestations of the COVID-19 virus have been well documented in the literature. This is thought to be multifactorial in nature through the virus' neurotropic properties and the body's inflammatory response to infection.

• However, possible neuropsychiatric symptoms following vaccination appear to be rare.

• We present a case of new onset mania with psychotic features following vaccination.

#### Case

- Patient is a 66-year-old female with no past psychiatric history who was medically admitted for altered mental status and agitation following her second BNT162b2 vaccination.
- Symptoms began one day later, described as dizziness, headache, and memory impairment, with progression to decreased need for sleep and bizarre behaviors.
- She was medically admitted for evaluation of symptoms, with initial concern for delirium due to impaired attention, awareness, and behavioral change.
- She was discharged home, but over the next 48 hours she was increasingly labile, religiously preoccupied, and grandiose prompting readmission.
- At time of readmission, her clinical presentation did not appear to be consistent with delirium, as attention and awareness were intact.
- Psychiatry was consulted for evaluation of mania.

### **COVID** Vaccine **Medical Admiss**

Confusion, perseveration

**Discharged Hom** 

Agitation, disorgar

**Medical Admiss** 

 Pressured speech delusions

Inpatient Psychi 6/25/21

Inpatient Psychi 7/23/21

 Decreased need for aggression toward

Inpatient Psychi 8/25/21

- Mood lability, decrease into checking accou items), compulsion
- Discharged on lithi 25 mg BID, lorazep

- week period.

| #2 – 6/8/21  | Outpatient Follow-Up #1 – 9/28/21  |
|--|--|
| sion #1 – 6/18/21 to 6/19/21   | <ul> <li>Cognitive slowing, memory impairment surrounding<br/>hospitalizations, fatigue, anxiety, new hypothyroidism</li> <li>Lorazepam decreased to 0.5 mg QHS</li> </ul> |
| verative speech, visual hallucinations   | Outpatient Follow-Up #2 – 11/9/21  |
| ne   | <ul> <li>Fatigued, but improved cognitive clouding, anxiety</li> <li>Quetiapine decreased to 25 mg QHS</li> </ul>  |
|  | Outpatient Follow-Up #3 – 12/14/21   |
| nized speech   | Improved attention, more spontaneous   |
| sion #2 – 6/21/21 to 6/24/21   | Quetiapine decreased to 12.5 mg QHS     Outpatient Follow-Up #4-5 – 2/22/22 & 4/19/22  |
| n, mood lability, grandiose and paranoid   | <ul> <li>Continued improvement in affective reactivity, cognitive<br/>clouding, but having panic attacks</li> </ul>  |
| iatric Admission #1 – 6/24/21 to   | <ul> <li>Quetiapine discontinued; lorazepam increased to 0.5 mg<br/>QHS with 0.5 mg daily PRN breakthrough</li> </ul>  |
| iatric Admission #2 – 6/25/21 to   | Outpatient Follow-Up #6 – 7/11/22  |
|  | <ul> <li>Subjective improvement in affective range for first time<br/>since index hospitalization</li> </ul>   |
| for sleep, religious preoccupation, ds staff   | <ul> <li>Started psychotherapy</li> <li>Levothyroxine started</li> </ul>   |
| iatric Admission #3 – 8/11/21 to   | COVID Infection – 8/2/22   |
| record need for alcongeture of the set of th | <ul> <li>No recurrence of mania despite dexamethasone treatment</li> </ul>   |
| reased need for sleep, transferred \$245K<br>ount, disorganized behavior (throwing<br>ons (handwashing, door checking)   | Outpatient Follow-Up #7 – 9/12/22  |
| nium 300 mg QHS (level 0.7), quetiapine<br>epam 0.5 mg BID   | <ul><li>Improved anxiety, attention</li><li>Gabapentin added by pain management</li></ul>  |
|  |  |


### Results

• During her admission, COVID-19 testing was negative by PCR, and labs were unremarkable. • Lumbar puncture was negative for an infectious cause of symptoms. CTA head and MRI brain were without acute findings. EEG showed mild cortical dysfunction in the left temporal region, without evidence of epileptiform discharges or seizures.

Symptoms of mania worsened to include aggression, excessive spending, and development of both checking and handwashing behaviors.

• These behaviors prompted three psychiatric admissions and multiple medication trials over an eight-

• Ultimately, symptoms resolved with a combination of lithium, quetiapine, and lorazepam.



& Immunity - Health. 2021;18:100363.